Media coverage about Biomed Realty Trust (NYSE:BMR) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biomed Realty Trust earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the real estate investment trust an impact score of 45.0977399664273 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Biomed Realty Trust (BMR) traded up $0.04 on Thursday, reaching $23.81. 11,841,100 shares of the company traded hands, compared to its average volume of 7,187,771. Biomed Realty Trust has a 52 week low of $17.94 and a 52 week high of $25.08.

WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at

About Biomed Realty Trust

BioMed Realty Trust, Inc operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company’s tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry.

Insider Buying and Selling by Quarter for Biomed Realty Trust (NYSE:BMR)

Receive News & Ratings for Biomed Realty Trust Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomed Realty Trust Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.